<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="bd53ab8c-821a-4a1b-bcda-4fed3bbd6382"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>These highlights do not include all the information needed to use DARIFENACIN EXTENDED-RELEASE TABLETS safely and effectively. See full prescribing information for DARIFENACIN EXTENDED-RELEASE TABLETS. <br/>
      <br/> DARIFENACIN extended-release tablets, for oral use <br/>
      <br/> Initial U.S. Approval:2004</title>
   <effectiveTime value="20250421"/>
   <setId root="e84f1ae3-b9a2-4a15-a299-c75373891cc1"/>
   <versionNumber value="9"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id root="1.3.6.1.4.1.519.1" extension="650175722"/>
            <name>Torrent Pharmaceuticals Limited</name>
            <assignedEntity>
               <assignedOrganization>
                  <id root="1.3.6.1.4.1.519.1" extension="790033935"/>
                  <name>Torrent Pharma, Inc</name>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="916488547"/>
                        <name>Torrent Pharmaceuticals Limited</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C43360" displayName="manufacture" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="13668-202" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" displayName="manufacture" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="13668-203" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="dc6454cd-be36-a9e6-e053-2a95a90ae23e"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL product data elements section"/>
               <effectiveTime value="20220411"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="13668-202" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Darifenacin</name>
                        <formCode code="C42927" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET, EXTENDED RELEASE"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Darifenacin</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="OP1R32D61U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CELLULOSE, MICROCRYSTALLINE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="39J80LT57T" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYPROMELLOSE 2208 (4000 MPA.S)</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="36SFW2JZ0W" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYPROMELLOSE 2910 (15 MPA.S)</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MAGNESIUM STEARATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="B697894SGQ" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYETHYLENE GLYCOL 400</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="ETJ7Z6XBU4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SILICON DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="7SEV7J4R1U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TALC</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="15FIX9V2JP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TITANIUM DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIM">
                           <quantity>
                              <numerator unit="mg" value="7.5"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="CR02EYQ8GV" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>DARIFENACIN HYDROBROMIDE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="APG9819VLM" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>DARIFENACIN</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="30" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="13668-202-30" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20161118"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="90" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="13668-202-90" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20161118"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="500" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="13668-202-05" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20161118"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA205209" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20161118"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48325" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="white" xsi:type="CE"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48348" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ROUND" xsi:type="CE"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="8" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">202</value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="13668-203" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Darifenacin</name>
                        <formCode code="C42927" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET, EXTENDED RELEASE"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Darifenacin</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="OP1R32D61U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CELLULOSE, MICROCRYSTALLINE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="1K09F3G675" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FERRIC OXIDE RED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="EX438O2MRT" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FERRIC OXIDE YELLOW</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="39J80LT57T" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYPROMELLOSE 2208 (4000 MPA.S)</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="36SFW2JZ0W" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYPROMELLOSE 2910 (15 MPA.S)</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MAGNESIUM STEARATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="B697894SGQ" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYETHYLENE GLYCOL 400</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="ETJ7Z6XBU4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SILICON DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="7SEV7J4R1U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TALC</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="15FIX9V2JP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TITANIUM DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIM">
                           <quantity>
                              <numerator unit="mg" value="15"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="CR02EYQ8GV" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>DARIFENACIN HYDROBROMIDE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="APG9819VLM" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>DARIFENACIN</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="30" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="13668-203-30" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20161118"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="500" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="13668-203-05" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20161118"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="90" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="13668-203-90" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20161118"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA205209" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20161118"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48331" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="orange" xsi:type="CE">
                              <originalText>Light peach</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48348" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ROUND" xsi:type="CE"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="8" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">203</value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="ID1">
               <id root="7a5e3d5b-4996-4e7c-8b7e-d38bd90bbdcd"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE</title>
               <text>
                  <paragraph ID="ID8">Darifenacin extended-release tablets are indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency and frequency.</paragraph>
               </text>
               <effectiveTime value="20250424"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph ID="ID7">Darifenacin extended-release tablets are a muscarinic antagonist indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency and frequency. (<content styleCode="underline">
                              <linkHtml href="#ID1">1</linkHtml>
                           </content>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID2">
               <id root="0d8c72d6-e752-405b-95fa-f3ec150daa71"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION</title>
               <text>
                  <paragraph ID="ID11">The recommended starting dose of darifenacin extended-release tablets is 7.5 mg orally once daily. Based upon individual response, the dose may be increased to 15 mg once daily, as early as two weeks after starting therapy.</paragraph>
                  <paragraph>Darifenacin extended-release tablets should be taken orally once daily with water. Darifenacin extended-release tablets may be taken with or without food, and should be swallowed whole and not chewed, divided or crushed.</paragraph>
                  <paragraph>For patients with moderate hepatic impairment (Child-Pugh B) or when co-administered with potent CYP3A4 inhibitors (for example, ketoconazole, itraconazole, ritonavir, nelfinavir, clarithromycin and nefazadone), the daily dose of darifenacin extended-release tablets should not exceed 7.5 mg. Darifenacin extended-release tablets are not recommended for use in patients with severe hepatic impairment (Child-Pugh C) 
       
 
  
       
 
  <content styleCode="italics">[see Warnings &amp; Precautions (
        
  
   
        
  
   <linkHtml href="#ID51">5.6</linkHtml>), Drug Interactions (
        
  
   
        
  
   <linkHtml href="#ID54">7.1</linkHtml>), Use in Specific Populations (
        
  
   
        
  
   <linkHtml href="#ID67">8.6</linkHtml>) and Clinical Pharmacology (
        
  
   
        
  
   <linkHtml href="#ID73">12.3</linkHtml>)]
       
 
  
       
 
  </content>.
      

 
      

 </paragraph>
               </text>
               <effectiveTime value="20250422"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph ID="ID10">The recommended starting dose of darifenacin extended-release tablets is 7.5 mg once daily. Based upon individual response, the dose may be increased to 15 mg once daily, as early as two weeks after starting therapy (<content styleCode="underline">
                              <linkHtml href="#ID2">2</linkHtml>
                           </content>)  </paragraph>
                        <paragraph>The daily dose of darifenacin extended-release tablets should not exceed 7.5 mg in the following patients:</paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>  Patients with moderate hepatic impairment (Child-Pugh B) (<content styleCode="underline">2</content>, <content styleCode="underline">
                                 <linkHtml href="#ID67">8.6</linkHtml>
                              </content>)</item>
                           <item>  Patients taking potent CYP3A4 inhibitors (<content styleCode="underline">2</content>, <content styleCode="underline">
                                 <linkHtml href="#ID54">7.1</linkHtml>
                              </content>)</item>
                        </list>
                        <paragraph ID="ID13">Darifenacin extended-release tablets is not recommended for use in patients with severe hepatic impairment (Child-Pugh C) (<content styleCode="underline">2</content>, <content styleCode="underline">
                              <linkHtml href="#ID67">8.6</linkHtml>
                           </content>)</paragraph>
                        <paragraph>Darifenacin extended-release tablets may be taken with or without food. The tablet should be swallowed whole with water and not chewed, divided or crushed (<content styleCode="underline">
                              <linkHtml href="#ID2">2</linkHtml>
                           </content>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID3">
               <id root="704dcd0d-c9e2-4b73-8b0c-3dc8434fc35f"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS</title>
               <text>
                  <paragraph ID="ID25">Darifenacin extended-release tablets 7.5 mg are white to off-white colored, round, biconvex, bevel edged, film coated tablets, debossed "202" on one side and plain on other side.</paragraph>
                  <paragraph>Darifenacin extended-release tablets 15 mg are light peach colored, round, biconvex, bevel edged, film coated tablets, debossed "203" on one side and plain on other side.</paragraph>
               </text>
               <effectiveTime value="20250424"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph ID="ID24">Extended-release tablets 7.5 mg and 15 mg (<content styleCode="underline">
                              <linkHtml href="#ID3">3</linkHtml>
                           </content>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID4">
               <id root="8e174da6-ddc9-4d77-9f4c-fd34ff9d898e"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS</title>
               <text>
                  <paragraph ID="ID43">Darifenacin extended-release tablets are contraindicated in patients with, or at risk for, the following conditions:</paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>  urinary retention</item>
                     <item>  gastric retention, or</item>
                     <item>  uncontrolled narrow-angle glaucoma.</item>
                  </list>
               </text>
               <effectiveTime value="20250422"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph ID="ID29">Darifenacin extended-release tablets is contraindicated in patients with, or at risk for, the following conditions (<content styleCode="underline">
                              <linkHtml href="#ID4">4</linkHtml>
                           </content>):</paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>  urinary retention,</item>
                           <item>  gastric retention, or</item>
                           <item>  uncontrolled narrow-angle glaucoma.</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID5">
               <id root="118a1901-af80-4d17-898c-0e41381681a0"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS</title>
               <effectiveTime value="20250424"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>Darifenacin extended-release tablets should be administered with caution to patients with clinically significant bladder outflow obstruction because of the risk of urinary retention ( <content styleCode="underline">
                                 <linkHtml href="#ID45">5.1</linkHtml>
                              </content>)</item>
                           <item>Darifenacin extended-release tablets should be administered with caution to patients with gastrointestinal obstructive disorders because of the risk of gastric retention ( <content styleCode="underline">
                                 <linkHtml href="#ID47">5.2</linkHtml>
                              </content>)</item>
                           <item>Darifenacin extended-release tablets should be used with caution in patients being treated for narrow-angle glaucoma and only where the potential benefits outweigh the risks ( <content styleCode="underline">
                                 <linkHtml href="#ID48">5.3</linkHtml>
                              </content>)</item>
                           <item>Central Nervous System Effects: Somnolence has been reported with darifenacin. Advise patients not to drive or operate heavy machinery until they know how darifenacin affects them ( <content styleCode="underline">
                                 <linkHtml href="#ID50">5.5</linkHtml>
                              </content>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID45">
                     <id root="8e575ae7-4e32-464c-92b5-00df249ea3e0"/>
                     <title>5.1 Risk of Urinary Retention</title>
                     <text>
                        <paragraph ID="ID75">Darifenacin extended-release tablets should be administered with caution to patients with clinically significant bladder outflow obstruction because of the risk of urinary retention.</paragraph>
                     </text>
                     <effectiveTime value="20250424"/>
                  </section>
               </component>
               <component>
                  <section ID="ID47">
                     <id root="dc64529c-74e5-2779-e053-2a95a90adab4"/>
                     <title>5.2 Decreased Gastrointestinal Motility</title>
                     <text>
                        <paragraph ID="ID76">Darifenacin extended-release tablets should be administered with caution to patients with gastrointestinal obstructive disorders because of the risk of gastric retention. Darifenacin extended-release tablets, like other anticholinergic drugs, may decrease gastrointestinal motility and should be used with caution in patients with conditions such as severe constipation, ulcerative colitis, and myasthenia gravis.</paragraph>
                     </text>
                     <effectiveTime value="20161121"/>
                  </section>
               </component>
               <component>
                  <section ID="ID48">
                     <id root="dc64529c-74e6-2779-e053-2a95a90adab4"/>
                     <title>5.3 Controlled Narrow-Angle Glaucoma</title>
                     <text>
                        <paragraph ID="ID77">Darifenacin extended-release tablets should be used with caution in patients being treated for narrow-angle glaucoma and only where the potential benefits outweigh the risks.</paragraph>
                     </text>
                     <effectiveTime value="20161121"/>
                  </section>
               </component>
               <component>
                  <section ID="ID49">
                     <id root="dc64529c-74e7-2779-e053-2a95a90adab4"/>
                     <title>5.4 Angioedema</title>
                     <text>
                        <paragraph ID="ID78">Angioedema of the face, lips, tongue, and/or larynx have been reported with darifenacin. In some cases angioedema occurred after the first dose. Angioedema associated with upper airway swelling may be life threatening. If involvement of the tongue, hypopharynx, or larynx occurs, darifenacin should be promptly discontinued and appropriate therapy and/or measures necessary to ensure a patent airway should be promptly provided.</paragraph>
                     </text>
                     <effectiveTime value="20161121"/>
                  </section>
               </component>
               <component>
                  <section ID="ID50">
                     <id root="dc64529c-74e8-2779-e053-2a95a90adab4"/>
                     <title>5.5 Central Nervous System Effects</title>
                     <text>
                        <paragraph ID="ID79">Darifenacin extended-release tablets are associated with anticholinergic central nervous system (CNS) effects 
         
 
  
         
 
  <content styleCode="italics">[see Adverse Reactions (
          
  
   
          
  
   <linkHtml href="#ID53">6.2</linkHtml>)]
         
 
  
         
 
  </content>. A variety of CNS anticholinergic effects have been reported, including headache, confusion, hallucinations and somnolence. Patients should be monitored for signs of anticholinergic CNS effects, particularly after beginning treatment or increasing the dose. Advise patients not to drive or operate heavy machinery until they know how darifenacin extended-release tablets affect them. If a patient experiences anticholinergic CNS effects, dose reduction or drug discontinuation should be considered.
        

 
        

 </paragraph>
                     </text>
                     <effectiveTime value="20210810"/>
                  </section>
               </component>
               <component>
                  <section ID="ID51">
                     <id root="dc64529c-74e9-2779-e053-2a95a90adab4"/>
                     <title>5.6 Patients with Hepatic Impairment</title>
                     <text>
                        <paragraph ID="ID80">The daily dose of darifenacin extended-release tablets should not exceed 7.5 mg for patients with moderate hepatic impairment (Child-Pugh B). Darifenacin extended-release tablets have not been studied in patients with severe hepatic impairment (Child-Pugh C) and therefore is not recommended for use in this patient population 
         
 
  
         
 
  <content styleCode="italics">[see Dosage and Administration (2) Use in Specific Populations (
          
  
   
          
  
   <linkHtml href="#ID67">8.6</linkHtml>) and Clinical Pharmacology (
          
  
   
          
  
   <linkHtml href="#ID72">12.3</linkHtml>)]
         
 
  
         
 
  </content>.
        

 
        

 </paragraph>
                     </text>
                     <effectiveTime value="20210810"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID14">
               <id root="a6eb8920-fb3e-4034-9836-f3d7b155e9a3"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS</title>
               <effectiveTime value="20250422"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>The most frequently reported adverse reactions (greater than 3 %) for darifenacin extended-release tablets are: constipation, dry mouth, headache, dyspepsia, nausea, urinary tract infection, accidental injury, and flu symptoms ( <content styleCode="underline">
                              <linkHtml href="#ID14">6</linkHtml>
                           </content>)</paragraph>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact TORRENT PHARMA INC. at 1-800-912-9561 or FDA at 1-800-FDA-1088 or </content>
                           <content styleCode="underline">www.fda.gov/medwatch</content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID52">
                     <id root="73591866-3235-4622-a056-45e87a86888e"/>
                     <title>6.1 Clinical Trials Experience</title>
                     <text>
                        <paragraph ID="ID81">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</paragraph>
                        <paragraph>The safety of darifenacin was evaluated in controlled clinical trials in a total of 8,830 patients, 6,001 of whom were treated with darifenacin. Of this total, 1,069 patients participated in three, 12-week, randomized, placebo-controlled, fixed-dose efficacy and safety studies (Studies 1, 2 and 3). Of this total, 337 and 334 patients received darifenacin 7.5 mg daily and 15 mg daily, respectively. In all long-term trials combined, 1,216 and 672 patients received treatment with darifenacin for at least 24 and 52 weeks, respectively.</paragraph>
                        <paragraph>In Studies 1, 2 and 3 combined, the serious adverse reactions to darifenacin were urinary retention and constipation.</paragraph>
                        <paragraph>In Studies 1, 2 and 3 combined, dry mouth leading to study discontinuation occurred in 0 %, 0.9 %, and 0 % of patients treated with darifenacin 7.5 mg daily, darifenacin 15 mg daily and placebo, respectively. Constipation leading to study discontinuation occurred in 0.6 %, 1.2 %, and 0.3 % of patients treated with darifenacin 7.5 mg daily, darifenacin 15 mg daily and placebo, respectively.</paragraph>
                        <paragraph>Table 1 lists the rates of identified adverse reactions, derived from all reported adverse events in 2 % or more of patients treated with 7.5 mg or 15 mg darifenacin, and greater than placebo in Studies 1, 2 and 3. In these studies, the most frequently reported adverse reactions were dry mouth and constipation. The majority of the adverse reactions were mild or moderate in severity and most occurred during the first two weeks of treatment.</paragraph>
                        <table ID="ID82" width="100%">
                           <caption> Table 1: Incidence of Identified Adverse Reactions, Derived from All Adverse Events Reported in greater than or equal to 2 % of Patients Treated with Darifenacin Extended-Release Tablets and More Frequent with Darifenacin than with Placebo in Studies 1, 2, and 3 </caption>
                           <colgroup>
                              <col width="17%"/>
                              <col width="27%"/>
                              <col width="19%"/>
                              <col width="17%"/>
                              <col width="17%"/>
                           </colgroup>
                           <tbody>
                              <tr>
                                 <td styleCode="Botrule" align="left" valign="top">
                                    <content styleCode="bold"> Body System</content>
                                 </td>
                                 <td styleCode="Botrule" align="left" valign="top">
                                    <content styleCode="bold"> A</content>
                                    <content styleCode="bold"> d</content>
                                    <content styleCode="bold"> v</content>
                                    <content styleCode="bold"> er</content>
                                    <content styleCode="bold"> se Reaction</content>
                                 </td>
                                 <td styleCode="Botrule" colspan="3" align="center" valign="top">
                                    <content styleCode="bold"> % age of Subjects</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule" valign="top"/>
                                 <td styleCode="Botrule" valign="top"/>
                                 <td styleCode="Botrule" align="center" valign="top">
                                    <content styleCode="bold"> Darifenacin</content>
                                    <br/>
                                    <content styleCode="bold"> 7.5 mg</content>
                                    <br/>
                                    <content styleCode="bold"> N = 337</content>
                                 </td>
                                 <td styleCode="Botrule" align="center" valign="top">
                                    <content styleCode="bold"> Darifenacin</content>
                                    <br/>
                                    <content styleCode="bold"> 15 mg</content>
                                    <br/>
                                    <content styleCode="bold"> N = 334</content>
                                 </td>
                                 <td styleCode="Botrule" align="center" valign="top">
                                    <content styleCode="bold"> Placebo</content>
                                    <br/>
                                    <content styleCode="bold"> N = 388</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top">
                                    <content styleCode="bold"> Digestive</content>
                                 </td>
                                 <td align="left" valign="top">Dry Mouth</td>
                                 <td align="center" valign="top">20.2</td>
                                 <td align="center" valign="top">35.3</td>
                                 <td align="center" valign="top">8.2</td>
                              </tr>
                              <tr>
                                 <td valign="top"/>
                                 <td align="left" valign="top">Constipation</td>
                                 <td align="center" valign="top">14.8</td>
                                 <td align="center" valign="top">21.3</td>
                                 <td align="center" valign="top">6.2</td>
                              </tr>
                              <tr>
                                 <td valign="top"/>
                                 <td align="left" valign="top">Dyspepsia</td>
                                 <td align="center" valign="top">2.7</td>
                                 <td align="center" valign="top">8.4</td>
                                 <td align="center" valign="top">2.6</td>
                              </tr>
                              <tr>
                                 <td valign="top"/>
                                 <td align="left" valign="top">Abdominal Pain</td>
                                 <td align="center" valign="top">2.4</td>
                                 <td align="center" valign="top">3.9</td>
                                 <td align="center" valign="top">0.5</td>
                              </tr>
                              <tr>
                                 <td valign="top"/>
                                 <td align="left" valign="top">Nausea</td>
                                 <td align="center" valign="top">2.7</td>
                                 <td align="center" valign="top">1.5</td>
                                 <td align="center" valign="top">1.5</td>
                              </tr>
                              <tr>
                                 <td valign="top"/>
                                 <td align="left" valign="top">Diarrhea</td>
                                 <td align="center" valign="top">2.1</td>
                                 <td align="center" valign="top">0.9</td>
                                 <td align="center" valign="top">1.8</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top">
                                    <content styleCode="bold"> Urogenital</content>
                                 </td>
                                 <td align="left" valign="top">Urinary Tract Infection</td>
                                 <td align="center" valign="top">4.7</td>
                                 <td align="center" valign="top">4.5</td>
                                 <td align="center" valign="top">2.6</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top">
                                    <content styleCode="bold"> Nervous</content>
                                 </td>
                                 <td align="left" valign="top">Dizziness</td>
                                 <td align="center" valign="top">0.9</td>
                                 <td align="center" valign="top">2.1</td>
                                 <td align="center" valign="top">1.3</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top">
                                    <content styleCode="bold"> Body as a  Whole</content>
                                 </td>
                                 <td align="left" valign="top">Asthenia</td>
                                 <td align="center" valign="top">1.5</td>
                                 <td align="center" valign="top">2.7</td>
                                 <td align="center" valign="top">1.3</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule" align="left" valign="top">
                                    <content styleCode="bold"> Eye</content>
                                 </td>
                                 <td styleCode="Botrule" align="left" valign="top">Dry Eyes</td>
                                 <td styleCode="Botrule" align="center" valign="top">1.5</td>
                                 <td styleCode="Botrule" align="center" valign="top">2.1</td>
                                 <td styleCode="Botrule" align="center" valign="top">0.5</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph ID="ID83">Other adverse reactions reported by 1% to 2% of darifenacin-treated patients include: abnormal vision, accidental injury, back pain, dry skin, flu syndrome, hypertension, vomiting, peripheral edema, weight gain, arthralgia, bronchitis, pharyngitis, rhinitis, sinusitis, rash, pruritus, urinary tract disorder and vaginitis.</paragraph>
                        <paragraph>Study 4 was a randomized, 12-week, placebo-controlled, dose-titration regimen study in which darifenacin was administered in accordance with dosing recommendations <content styleCode="italics">[see Dosage and Administration (2)]</content>. All patients initially received placebo or darifenacin 7.5 mg daily, and after two weeks, patients and physicians were allowed to adjust upward to darifenacin 15 mg if needed. In this study, the most commonly reported adverse reactions were also constipation and dry mouth. Table 2 lists the identified adverse reactions, derived from all adverse events reported in greater than 3% of patients treated with darifenacin and greater than placebo.</paragraph>
                        <table ID="ID84" width="100%">
                           <caption> Table 2: Number (%) of Adverse Reactions, Derived from All Adverse Events Reported in greater than 3% of Patients Treated with Darifenacin Extended-Release Tablets, and More Frequent with Darifenacin than Placebo, in Study 4 </caption>
                           <colgroup>
                              <col width="36%"/>
                              <col width="35%"/>
                              <col width="28%"/>
                           </colgroup>
                           <tbody>
                              <tr>
                                 <td align="center">
                                    <content styleCode="bold"> A</content>
                                    <content styleCode="bold"> d</content>
                                    <content styleCode="bold"> v</content>
                                    <content styleCode="bold"> er</content>
                                    <content styleCode="bold"> se Reaction</content>
                                 </td>
                                 <td align="center">
                                    <content styleCode="bold"> Darifenacin 7.5 mg/15 mg</content>
                                 </td>
                                 <td align="left">
                                    <content styleCode="bold"> Placebo</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center"/>
                                 <td align="center">
                                    <content styleCode="bold"> N = 268</content>
                                 </td>
                                 <td align="left">
                                    <content styleCode="bold"> N = 127</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule" align="left" valign="top">Constipation</td>
                                 <td styleCode="Toprule" align="center">56 (20.9 %)</td>
                                 <td styleCode="Toprule" align="left">10 (7.9 %)</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top">Dry Mouth</td>
                                 <td align="center">50 (18.7 %)</td>
                                 <td align="left">11 (8.7 %)</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top">Headache</td>
                                 <td align="center">18 (6.7 %)</td>
                                 <td align="left">7 (5.5 %)</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top">Dyspepsia</td>
                                 <td align="center">12 (4.5 %)</td>
                                 <td align="left">2 (1.6 %)</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top">Nausea</td>
                                 <td align="center">11 (4.1 %)</td>
                                 <td align="left">2 (1.6 %)</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top">Urinary Tract Infection</td>
                                 <td align="center">10 (3.7 %)</td>
                                 <td align="left">4 (3.1 %)</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top">Accidental Injury</td>
                                 <td align="center">8 (3.0 %)</td>
                                 <td align="left">3 (2.4 %)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule" align="left" valign="top">Flu Syndrome</td>
                                 <td styleCode="Botrule" align="center">8 (3.0 %)</td>
                                 <td styleCode="Botrule" align="left">3 (2.4 %)</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph/>
                     </text>
                     <effectiveTime value="20250421"/>
                  </section>
               </component>
               <component>
                  <section ID="ID53">
                     <id root="f258cc8d-cfe2-4d79-867b-56ab0e97ca0c"/>
                     <title>6.2 Post Marketing Experience</title>
                     <text>
                        <paragraph ID="ID85">The following adverse reactions have been reported during post-approval use of darifenacin extended-release tablets. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate frequency or establish a causal relationship to drug exposure.</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Dermatologic: </content>
                           </content>erythema multiforme, interstitial granuloma annulare</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">General: </content>
                           </content>hypersensitivity reactions, including angioedema with airway obstruction and anaphylactic reaction</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Central Nervous: </content>
                           </content>confusion, hallucinations and somnolence</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Cardiovascular: </content>
                           </content>palpitations and syncope</paragraph>
                     </text>
                     <effectiveTime value="20250422"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID15">
               <id root="a9609941-ade5-4d12-9ee3-aca62eef2d6b"/>
               <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
               <title>7 DRUG INTERACTIONS</title>
               <effectiveTime value="20250422"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>  Caution should be taken when darifenacin extended-release tablets is used concomitantly with medications that are predominantly metabolized by CYP2D6 and which have a narrow therapeutic window, such as flecainide, thioridazine and tricyclic antidepressants (<content styleCode="underline">7.2</content>)</item>
                           <item>  The concomitant use of darifenacin extended-release tablets with other anticholinergic agents may increase the frequency and/or severity of dry mouth, constipation, blurred vision and other anticholinergic pharmacological effects. Anticholinergic agents may potentially alter the absorption of some concomitantly administered drugs due to effects of gastrointestinal motility (<content styleCode="underline">7.3</content>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID54">
                     <id root="d3a24ec8-e187-4862-9346-077411c4c8d3"/>
                     <title>7.1 CYP3A4 Inhibitors</title>
                     <text>
                        <paragraph ID="ID86">The systemic exposure of darifenacin from darifenacin extended-release tablets is increased in the presence of CYP3A4 inhibitors. The daily dose of darifenacin extended-release tablets should not exceed 7.5 mg when co-administered with potent CYP3A4 inhibitors (for example, ketoconazole, itraconazole, ritonavir, nelfinavir, clarithromycin and nefazadone). No dosing adjustments are recommended in the presence of moderate CYP3A4 inhibitors (for example, erythromycin, fluconazole, diltiazem and verapamil) <content styleCode="italics">[see Dosage and Administration (2) and Clinical Pharmacology (12.3)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250422"/>
                  </section>
               </component>
               <component>
                  <section ID="ID55">
                     <id root="dc64529c-74ef-2779-e053-2a95a90adab4"/>
                     <title>7.2 CYP2D6 Inhibitors</title>
                     <text>
                        <paragraph ID="ID87">No dosing adjustments are recommended in the presence of CYP2D6 inhibitors (for example, paroxetine, fluoxetine, quinidine and duloxetine) 
         
 
  
         
 
  <content styleCode="italics">[see Clinical Pharmacology (12.3)]</content>.
        

 
        

 </paragraph>
                     </text>
                     <effectiveTime value="20161121"/>
                  </section>
               </component>
               <component>
                  <section ID="ID56">
                     <id root="dc64529c-74f0-2779-e053-2a95a90adab4"/>
                     <title>7.3 CYP2D6 Substrates</title>
                     <text>
                        <paragraph ID="ID88">Caution should be taken when darifenacin extended-release tablets are used concomitantly with medications that are predominantly metabolized by CYP2D6 and which have a narrow therapeutic window (for example, flecainide, thioridazine and tricyclic antidepressants) 
         
 
  
         
 
  <content styleCode="italics">[see Clinical Pharmacology (12.3)]</content>.
        

 
        

 </paragraph>
                     </text>
                     <effectiveTime value="20161121"/>
                  </section>
               </component>
               <component>
                  <section ID="ID57">
                     <id root="dc64529c-74f1-2779-e053-2a95a90adab4"/>
                     <title>7.4 CYP3A4 Substrates</title>
                     <text>
                        <paragraph ID="ID89">Darifenacin (30 mg daily) did not have a significant impact on midazolam (7.5 mg) pharmacokinetics 
         
 
  
         
 
  <content styleCode="italics">[</content>
                           <content styleCode="italics">see Clinical Pharmacology (12.3)]</content>.
        

 
        

 </paragraph>
                     </text>
                     <effectiveTime value="20161121"/>
                  </section>
               </component>
               <component>
                  <section ID="ID58">
                     <id root="dc64529c-74f2-2779-e053-2a95a90adab4"/>
                     <title>7.5 Combination oral contraceptives</title>
                     <text>
                        <paragraph ID="ID90">Darifenacin (10 mg three times daily) had no effect on the pharmacokinetics of the combination oral contraceptives containing levonorgestrel and ethinyl estradiol 
         
 
  
         
 
  <content styleCode="italics">[see Clinical Pharmacology (12.3)]</content>.
        

 
        

 </paragraph>
                     </text>
                     <effectiveTime value="20161121"/>
                  </section>
               </component>
               <component>
                  <section ID="ID59">
                     <id root="dc64529c-74f3-2779-e053-2a95a90adab4"/>
                     <title>7.6 Warfarin</title>
                     <text>
                        <paragraph ID="ID91">Darifenacin had no significant effect on prothrombin time when a single dose of warfarin 30 mg was co-administered with darifenacin (30 mg daily) at steady-state. Standard therapeutic prothrombin time monitoring for warfarin should be continued.</paragraph>
                     </text>
                     <effectiveTime value="20161121"/>
                  </section>
               </component>
               <component>
                  <section ID="ID60">
                     <id root="dc64529c-74f4-2779-e053-2a95a90adab4"/>
                     <title>7.7 Digoxin</title>
                     <text>
                        <paragraph ID="ID92">Darifenacin (30 mg daily) did not have a clinically relevant effect on the pharmacokinetics of digoxin (0.25 mg) at steady-state. Routine therapeutic drug monitoring for digoxin should be continued 
         
 
  
         
 
  <content styleCode="italics">[see Clinical Pharmacology (12.3)]</content>.
        

 
        

 </paragraph>
                     </text>
                     <effectiveTime value="20161121"/>
                  </section>
               </component>
               <component>
                  <section ID="ID61">
                     <id root="dc64529c-74f5-2779-e053-2a95a90adab4"/>
                     <title>7.8 Other Anticholinergic Agents</title>
                     <text>
                        <paragraph ID="ID93">The concomitant use of darifenacin extended-release tablets with other anticholinergic agents may increase the frequency and/or severity of dry mouth, constipation, blurred vision and other anticholinergic pharmacological effects. Anticholinergic agents may potentially alter the absorption of some concomitantly administered drugs due to effects on gastrointestinal motility.</paragraph>
                     </text>
                     <effectiveTime value="20161121"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID16">
               <id root="cee0f928-1ec0-4763-a7d5-f0cb66b9d895"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS</title>
               <effectiveTime value="20250424"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>Pregnancy: Darifenacin extended-release tablets should be used during pregnancy only if the benefit to the mother outweighs the potential risk to the fetus ( <content styleCode="underline">
                                 <linkHtml href="#ID62">8.1</linkHtml>
                              </content>)</item>
                           <item>Nursing Mothers: It is not known whether darifenacin is excreted into human milk and therefore caution should be exercised before darifenacin extended-release tablets are administered to a nursing woman (<content styleCode="underline">8.3</content>)</item>
                           <item>Pediatric Use: The safety and effectiveness of darifenacin extended- release tablets in pediatric patients have not been established ( <content styleCode="underline">
                                 <linkHtml href="#ID65">8.4</linkHtml>
                              </content>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID62">
                     <id root="173f3bc0-a15e-42e2-bcfb-fc27a7c36e0a"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy</title>
                     <text>
                        <paragraph ID="ID94">
                           <content styleCode="underline">Risk Summary</content>
                        </paragraph>
                        <paragraph>There are no available data on darifenacin use in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes. In animal studies, darifenacin was not teratogenic in rats and rabbits at plasma exposures of free drug (via AUC) up to 59 and 28 times the maximum recommended human dose (MRHD) of 15 mg, respectively. Effects on embryofetal development were observed following administration of darifenacin during pregnancy (dilated ureter and/or kidney pelvis in rabbits at about 9 times the MRHD, post-implantation loss in rabbits at about 28 times, and delayed ossification in rats at about 59 times) and during pregnancy and lactation (developmental delays in rats at about 17 times the MRHD), which was associated with maternal toxicity (see Data). Dystocia was observed in rat dams at about 17 times the MRHD.</paragraph>
                        <paragraph>In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Data</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">﻿Animal Data</content>
                        </paragraph>
                        <paragraph>Embryofetal development studies were conducted with oral darifenacin in female rats (0, 3, 10, and 50 mg/kg/day) and rabbits (0, 3, 10, and 30 mg/kg/day) during the period of organogenesis (gestation days 6 to 17 in the rat and gestation days 6 to 18 in the rabbit).  Darifenacin was not teratogenic in rats and rabbits at plasma exposure of free drug (via AUC) up to 59 times and 28 times, respectively (doses up to 50 and 30 mg/kg/day, respectively) the maximum recommended human dose [MRHD] of 15 mg.</paragraph>
                        <paragraph>At approximately 59 times the MRHD in pregnant rats there was a delay in the ossification of the sacral and caudal vertebrae (associated with a decrease in maternal and pup body weight gains) which was not observed at an exposure approximately 13 times the AUC at the MRHD.  At five times the AUC (3 mg/kg/day), there were no effects on dams or pups.  </paragraph>
                        <paragraph>In pregnant rabbits, an exposure of darifenacin approximately 28 times the AUC at the MRHD of 15mg (30 mg/kg/day) was shown to increase post-implantation loss (associated with decreased maternal body weight gain), with a no effect level at 10 mg/kg/day (9 times the AUC at the MRHD). Dilated ureter and/or kidney pelvis was also observed in offspring at this highest dose along with urinary bladder dilation consistent with the pharmacological action of darifenacin, with one case observed at the mid dose of 10 mg/kg/day (9 times the MRHD).  No effect was observed at the lowest dose of 3 mg/kg/day (approximately 2.8 times the AUC at the MRHD).  </paragraph>
                        <paragraph>A pre- and post-natal development study was conducted with oral darifenacin in female rats (0, 3, 10, and 50 mg/kg/day) throughout gestation and lactation.  Decreased body weight gain and dystocia were observed in dams at 10 mg/kg/day) throughout gestation and lactation. Decreased body weight and dystocia were observed in dams at 10 mg/kg/day (approximately 17 times the MRHD) and above.  Slight developmental delays (surface righting reflex, incisor eruption, eyelid opening, vaginal opening, preputial separation) were observed in pups at these doses.  At 5 times the AUC at the MRHD (3 mg/kg/day), there were no effects on dams or pups.</paragraph>
                     </text>
                     <effectiveTime value="20250424"/>
                  </section>
               </component>
               <component>
                  <section ID="ID63">
                     <id root="f197ed9c-f242-4b5a-91f3-ec924ef92937"/>
                     <code code="77290-5" codeSystem="2.16.840.1.113883.6.1" displayName="LACTATION SECTION"/>
                     <title>8.2 Lactation</title>
                     <text>
                        <paragraph ID="ID95">
                           <content styleCode="underline">Risk Summary</content>
                        </paragraph>
                        <paragraph>﻿There are no data on the presence of darifenacin in human milk, the effects on the breastfed infant, or the effects of darifenacin on milk production.  Darifenacin is present in rat milk [see Data].  When a drug is present in animal milk, it is likely that the drug will be present in human milk.</paragraph>
                        <paragraph>The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for darifenacin and any potential adverse effects on the breastfed child from darifenacin or from the underlying maternal conditions.</paragraph>
                        <paragraph>
                           <content styleCode="underline">﻿Data</content>
                        </paragraph>
                        <paragraph>After a single oral dose of  <sup>﻿14</sup>﻿C radiolabeled darifenacin to lactating rats, darifenacin was detected in maternal milk.</paragraph>
                     </text>
                     <effectiveTime value="20250424"/>
                  </section>
               </component>
               <component>
                  <section ID="ID65">
                     <id root="13d0e8d1-f000-4138-9b1b-4234f6715192"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use</title>
                     <text>
                        <paragraph ID="ID96">The safety and effectiveness of darifenacin extended-release tablets in pediatric patients have not been established.</paragraph>
                     </text>
                     <effectiveTime value="20250424"/>
                  </section>
               </component>
               <component>
                  <section ID="ID66">
                     <id root="94f97ae5-a87c-4fd3-8253-c40e1f4175c5"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5 Geriatric Use</title>
                     <text>
                        <paragraph ID="ID97">In the fixed-dose, placebo-controlled, clinical studies, 30% of patients treated with darifenacin were over 65 years of age. No overall differences in safety or efficacy were observed between patients over 65 years (n = 207) and younger patients less than 65 years (n = 464). No dose adjustment is recommended for elderly patients <content styleCode="italics">[see Clinical Pharmacology ( <linkHtml href="#ID73">12.3</linkHtml>) and Clinical Studies ( <linkHtml href="#ID21">14</linkHtml>)] </content>.</paragraph>
                     </text>
                     <effectiveTime value="20220411"/>
                  </section>
               </component>
               <component>
                  <section ID="ID67">
                     <id root="7fb6aa32-6e82-470e-9690-2a63b2f15844"/>
                     <title>8.6 Hepatic Impairment</title>
                     <text>
                        <paragraph ID="ID98">Subjects with severe hepatic impairment (Child-Pugh C) have not been studied, therefore darifenacin extended-release tablets are not recommended for use in these patients <content styleCode="italics">[see Dosage and Administration (2) and Warnings and Precautions ( <linkHtml href="#ID51">5.6</linkHtml>)] </content>. The daily dose of darifenacin extended-release tablets should not exceed 7.5 mg once daily for patients with moderate hepatic impairment (Child-Pugh B) <content styleCode="italics">[see Dosage and Administration (2) and Warnings and Precautions ( <linkHtml href="#ID51">5.6</linkHtml>)] </content>. After adjusting for plasma protein binding, unbound darifenacin exposure was estimated to be 4.7-fold higher in subjects with moderate hepatic impairment than subjects with normal hepatic function. No dose adjustment is recommended for patients with mild hepatic impairment (Child-Pugh A).</paragraph>
                     </text>
                     <effectiveTime value="20220411"/>
                  </section>
               </component>
               <component>
                  <section ID="ID68">
                     <id root="bb78f0cf-d4e4-4591-95aa-c7c642157707"/>
                     <title>8.7 Renal Impairment</title>
                     <text>
                        <paragraph ID="ID99">A study of subjects with varying degrees of renal impairment (creatinine clearance between 10 and 136 mL/min) demonstrated no clear relationship between renal function and darifenacin clearance. No dose adjustment is recommended for patients with renal impairment <content styleCode="italics">[see Clinical Pharmacology ( <linkHtml href="#ID73">12.3</linkHtml>)] </content>.</paragraph>
                     </text>
                     <effectiveTime value="20250424"/>
                  </section>
               </component>
               <component>
                  <section ID="ID69">
                     <id root="dc64529c-74fd-2779-e053-2a95a90adab4"/>
                     <title>8.8 Gender</title>
                     <text>
                        <paragraph ID="ID100">No dose adjustment is recommended based on gender 
         
 
  <content styleCode="italics">[see Clinical Pharmacology (
          
  
   <linkHtml href="#ID73">12.3</linkHtml>) and Clinical Studies(
          
  
   <linkHtml href="#ID21">14</linkHtml>)]
         
 
  </content>.
        

 </paragraph>
                     </text>
                     <effectiveTime value="20220411"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID17">
               <id root="8e070d84-6303-421c-aed7-4224c6b8fcab"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>10 OVERDOSAGE</title>
               <text>
                  <paragraph ID="ID101">Overdosage with antimuscarinic agents, including darifenacin extended-release tablets, can result in severe antimuscarinic effects. Treatment should be symptomatic and supportive. In the event of overdosage, ECG monitoring is recommended. Darifenacin extended-release tablets has been administered in clinical trials at doses up to 75 mg (five times the maximum therapeutic dose) and signs of overdose were limited to abnormal vision.</paragraph>
               </text>
               <effectiveTime value="20250424"/>
            </section>
         </component>
         <component>
            <section ID="ID18">
               <id root="c58d4b37-12a5-424c-a5ae-0794f5888208"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION</title>
               <text>
                  <paragraph ID="ID102">Darifenacin extended-release tablet is an extended-release tablet for oral administration which contains 7.5 mg or 15 mg darifenacin as its hydrobromide salt. The active moiety, darifenacin, is a potent muscarinic receptor antagonist.</paragraph>
                  <paragraph>Chemically, darifenacin hydrobromide is <content styleCode="italics">(S)</content>-2-{1-[2-(2,3-dihydrobenzofuran-5-yl)ethyl]-3-pyrrolidinyl}-2,2-diphenylacetamide hydrobromide. The empirical formula of darifenacin hydrobromide is C <sub>28</sub>H <sub>30</sub>N <sub>2</sub>O <sub>2</sub>•HBr.</paragraph>
                  <paragraph>The structural formula is:</paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="Lc8ecc51c-2c6a-47bf-b6a6-c3e2a400960f"/>
                  </paragraph>
                  <paragraph/>
                  <paragraph ID="ID104">Darifenacin hydrobromide is a white to almost white to off-white powder, with a molecular weight of 507.5.</paragraph>
                  <paragraph>Darifenacin extended-release tablet is a once-a-day extended-release tablet and contains the following inactive ingredients: colloidal silicon dioxide, hypromellose (E15 LV), hypromellose (methocel K4M CR), magnesium stearate, microcrystalline cellulose, polyethylene glycol 400, talc and titanium dioxide. The 15 mg tablet also contains ferric oxide red and ferric oxide yellow.</paragraph>
               </text>
               <effectiveTime value="20250421"/>
               <component>
                  <observationMedia ID="Lc8ecc51c-2c6a-47bf-b6a6-c3e2a400960f">
                     <text>structure</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="structure.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID19">
               <id root="0dbc4fd0-bb4f-421d-a2f4-727ba60be753"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY</title>
               <effectiveTime value="20250424"/>
               <component>
                  <section ID="ID70">
                     <id root="5a9fee89-318f-4d11-b0f7-c0c5f73b99e2"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1 Mechanism of Action</title>
                     <text>
                        <paragraph ID="ID105">Darifenacin is a competitive muscarinic receptor antagonist. Muscarinic receptors play a role in cholinergically mediated functions, including contractions of the urinary bladder smooth muscle. </paragraph>
                        <paragraph>
                           <content styleCode="italics">In vitro </content>studies using human recombinant muscarinic receptor subtypes show that darifenacin has greater affinity for the M <sub>3</sub> receptor than for the other known muscarinic receptors (9- and 12-fold greater affinity for M <sub>3</sub> compared to M <sub>1</sub> and M <sub>5</sub>, respectively, and 59-fold greater affinity for M <sub>3</sub> compared to both M <sub>2</sub> and M <sub>4</sub>). M <sub>3</sub> receptors are involved in contraction of human bladder. </paragraph>
                     </text>
                     <effectiveTime value="20250424"/>
                  </section>
               </component>
               <component>
                  <section ID="ID72">
                     <id root="6966f036-b4b1-4329-9b12-04afd1cb3017"/>
                     <code code="43681-6" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACODYNAMICS SECTION"/>
                     <title>12.2 Pharmacodynamics</title>
                     <text>
                        <paragraph ID="ID106">In three cystometric studies performed in patients with involuntary detrusor contractions, increased bladder capacity was demonstrated by an increased volume threshold for unstable contractions and diminished frequency of unstable detrusor contractions after darifenacin extended-release tablet treatment. These findings are consistent with an antimuscarinic action on the urinary bladder.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Electrophysiology</content>
                        </paragraph>
                        <paragraph>The effect of a six-day treatment of 15 mg and 75 mg darifenacin on QT/QTc interval was evaluated in a multiple-dose, double-blind, randomized, placebo- and active-controlled (moxifloxacin 400 mg) parallel-arm design study in 179 healthy adults (44% male, 56% female) aged 18 to 65. Subjects included 18% poor metabolizers (PMs) and 82% extensive metabolizers (EMs). The QT interval was measured over a 24-hour period both predosing and at steady-state. The 75 mg darifenacin extended-release tablets dose was chosen because this achieves exposure similar to that observed in CYP2D6 poor metabolizers administered the highest recommended dose (15 mg) of darifenacin in the presence of a potent CYP3A4 inhibitor. At the doses studied, darifenacin did not result in QT/QTc interval prolongation at any time during the steady-state, while moxifloxacin treatment resulted in a mean increase from baseline QTcF of about 7.0 msec when compared to placebo. In this study, darifenacin 15 mg and 75 mg doses demonstrated a mean heart rate change of 3.1 and 1.3 bpm, respectively, when compared to placebo. However, in the clinical efficacy and safety studies, the change in median HR following treatment with darifenacin was no different from placebo.</paragraph>
                     </text>
                     <effectiveTime value="20250424"/>
                  </section>
               </component>
               <component>
                  <section ID="ID73">
                     <id root="e35657e5-c7b4-412e-9ea3-3902c9b9b6a5"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3 Pharmacokinetics</title>
                     <text>
                        <paragraph ID="ID107">
                           <content styleCode="bold">Absorption</content>
                        </paragraph>
                        <paragraph>After oral administration of darifenacin extended-release tablets to healthy volunteers, peak plasma concentrations of darifenacin are reached approximately seven hours after multiple dosing and steady-state plasma concentrations are achieved by the sixth day of dosing. The mean (SD) steady-state time course of darifenacin 7.5 mg and 15 mg extended-release tablets is depicted in Figure 1.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Figure 1 Mean (SD) Steady-State Darifenacin Plasma Concentration-Time Profiles for Darifenacin 7.5 mg and 15 mg in Healthy Volunteers Including Both CYP2D6 EMs and PMs*</content>
                        </paragraph>
                        <paragraph>
                           <renderMultiMedia referencedObject="Le484c485-96dc-4963-b188-69c7edcad78a"/>
                        </paragraph>
                        <paragraph/>
                        <paragraph ID="ID109">*Includes 95 EMs and 6 PMs for 7.5 mg; 104 EMs and 10 PMs for 15 mg.</paragraph>
                        <paragraph>A summary of mean (standard deviation, SD) steady-state pharmacokinetic parameters of darifenacin 7.5 mg and 15 mg extended-release tablets in EMs and PMs of CYP2D6 is provided in Table 3.</paragraph>
                        <table ID="ID110" width="617px">
                           <caption> Table 3: Mean (SD) Steady-State Pharmacokinetic Parameters from Darifenacin 7.5 mg and 15 mg Extended-Release Tablets Based on Pooled Data by Predicted CYP2D6 Phenotype </caption>
                           <colgroup>
                              <col width="33"/>
                              <col width="72"/>
                              <col width="60"/>
                              <col width="60"/>
                              <col width="47"/>
                              <col width="51"/>
                              <col width="72"/>
                              <col width="60"/>
                              <col width="60"/>
                              <col width="47"/>
                              <col width="58"/>
                           </colgroup>
                           <tbody>
                              <tr>
                                 <td styleCode="Botrule" align="left" valign="top"/>
                                 <td styleCode="Botrule Rrule" colspan="5" align="center" valign="top">
                                    <content styleCode="bold"> Darifenacin 7.5 mg</content>
                                    <br/>
                                    <content styleCode="bold"> (N = 68 EM, 5 PM)</content>
                                 </td>
                                 <td styleCode="Botrule" colspan="5" align="center" valign="top">
                                    <content styleCode="bold"> Darifenacin 15 mg</content>
                                    <br/>
                                    <content styleCode="bold"> (N = 102 EM, 17 PM)</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule" align="left" valign="top"/>
                                 <td styleCode="Botrule" align="left" valign="top">
                                    <content styleCode="bold"> A</content>
                                    <content styleCode="bold"> UC</content>
                                    <content styleCode="bold">
                                       <sub>24 </sub>
                                    </content>
                                    <content styleCode="bold"> (ng•h/mL)</content>
                                 </td>
                                 <td styleCode="Botrule" align="left" valign="top">
                                    <content styleCode="bold"> C</content>
                                    <content styleCode="bold">
                                       <sub>max</sub>
                                    </content>
                                    <br/>
                                    <content styleCode="bold"> (ng/mL)</content>
                                 </td>
                                 <td styleCode="Botrule" align="left" valign="top">
                                    <content styleCode="bold"> C</content>
                                    <content styleCode="bold">
                                       <sub>a</sub>
                                    </content>
                                    <content styleCode="bold">
                                       <sub>v</sub>
                                    </content>
                                    <content styleCode="bold">
                                       <sub>g</sub>
                                    </content>
                                    <br/>
                                    <content styleCode="bold"> (ng/mL)</content>
                                 </td>
                                 <td styleCode="Botrule" align="left" valign="top">
                                    <content styleCode="bold"> T</content>
                                    <content styleCode="bold">
                                       <sub>max</sub>
                                    </content>
                                    <br/>
                                    <content styleCode="bold"> (h)</content>
                                 </td>
                                 <td styleCode="Botrule Rrule" align="left" valign="top">
                                    <content styleCode="bold"> t</content>
                                    <content styleCode="bold">
                                       <sub>1/2</sub>
                                    </content>
                                    <br/>
                                    <content styleCode="bold"> (h)</content>
                                 </td>
                                 <td styleCode="Botrule" align="left" valign="top">
                                    <content styleCode="bold"> A</content>
                                    <content styleCode="bold"> UC</content>
                                    <content styleCode="bold">
                                       <sub>24 </sub>
                                    </content>
                                    <content styleCode="bold"> (ng•h/mL)</content>
                                 </td>
                                 <td styleCode="Botrule" align="left" valign="top">
                                    <content styleCode="bold"> C</content>
                                    <content styleCode="bold">
                                       <sub>max</sub>
                                    </content>
                                    <br/>
                                    <content styleCode="bold"> (ng/mL)</content>
                                 </td>
                                 <td styleCode="Botrule" align="left" valign="top">
                                    <content styleCode="bold"> C</content>
                                    <content styleCode="bold">
                                       <sub>a</sub>
                                    </content>
                                    <content styleCode="bold">
                                       <sub>v</sub>
                                    </content>
                                    <content styleCode="bold">
                                       <sub>g</sub>
                                    </content>
                                    <br/>
                                    <content styleCode="bold"> (ng/mL)</content>
                                 </td>
                                 <td styleCode="Botrule" align="left" valign="top">
                                    <content styleCode="bold"> T</content>
                                    <content styleCode="bold">
                                       <sub>max</sub>
                                    </content>
                                    <br/>
                                    <content styleCode="bold"> (h)</content>
                                 </td>
                                 <td styleCode="Botrule" align="left" valign="top">
                                    <content styleCode="bold"> t</content>
                                    <content styleCode="bold">
                                       <sub>1/2</sub>
                                    </content>
                                    <br/>
                                    <content styleCode="bold"> (h)</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top">
                                    <content styleCode="bold"> EM</content>
                                 </td>
                                 <td align="left" valign="top">29.24</td>
                                 <td align="left" valign="top">2.01</td>
                                 <td align="left" valign="top">1.22</td>
                                 <td align="left" valign="top">6.49</td>
                                 <td styleCode="Rrule" align="left" valign="top">12.43</td>
                                 <td align="left" valign="top">88.90</td>
                                 <td align="left" valign="top">5.76</td>
                                 <td align="left" valign="top">3.70</td>
                                 <td align="left" valign="top">7.61</td>
                                 <td align="left" valign="top">12.05</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule" align="left" valign="top"/>
                                 <td styleCode="Botrule" align="left" valign="top">(15.47)</td>
                                 <td styleCode="Botrule" align="left" valign="top">(1.04)</td>
                                 <td styleCode="Botrule" align="left" valign="top">(0.64)</td>
                                 <td styleCode="Botrule" align="left" valign="top">(4.19)</td>
                                 <td styleCode="Botrule Rrule" align="left" valign="top">(5.64) <sup>a </sup>
                                 </td>
                                 <td styleCode="Botrule" align="left" valign="top">(67.87)</td>
                                 <td styleCode="Botrule" align="left" valign="top">(4.24)</td>
                                 <td styleCode="Botrule" align="left" valign="top">(2.83)</td>
                                 <td styleCode="Botrule" align="left" valign="top">(5.06)</td>
                                 <td styleCode="Botrule" align="left" valign="top">(12.37) <sup>b</sup>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top">
                                    <content styleCode="bold"> PM</content>
                                 </td>
                                 <td align="left" valign="top">67.56</td>
                                 <td align="left" valign="top">4.27</td>
                                 <td align="left" valign="top">2.81</td>
                                 <td align="left" valign="top">5.20</td>
                                 <td styleCode="Rrule" align="left" valign="top">19.95 <sup>c</sup>
                                 </td>
                                 <td align="left" valign="top">157.71</td>
                                 <td align="left" valign="top">9.99</td>
                                 <td align="left" valign="top">6.58</td>
                                 <td align="left" valign="top">6.71</td>
                                 <td align="left" valign="top">7.40 <sup>d</sup>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule" align="left" valign="top"/>
                                 <td styleCode="Botrule" align="left" valign="top">(13.13)</td>
                                 <td styleCode="Botrule" align="left" valign="top">(0.98)</td>
                                 <td styleCode="Botrule" align="left" valign="top">(0.55)</td>
                                 <td styleCode="Botrule" align="left" valign="top">(1.79)</td>
                                 <td styleCode="Botrule Rrule" align="left" valign="top">-</td>
                                 <td styleCode="Botrule" align="left" valign="top">(77.08)</td>
                                 <td styleCode="Botrule" align="left" valign="top">(5.09)</td>
                                 <td styleCode="Botrule" align="left" valign="top">(3.22)</td>
                                 <td styleCode="Botrule" align="left" valign="top">(3.58)</td>
                                 <td styleCode="Botrule" align="left" valign="top">-</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule" colspan="11" align="left" valign="top">
                                    <sup>a</sup>N = 25; <sup>b</sup>N = 8; <sup>c</sup>N = 2; <sup>d</sup>N = 1; AUC <sub>24</sub> = Area under the plasma concentration versus time curve for 24h;</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule" colspan="11" align="left" valign="top">C <sub>max</sub>  = Maximum observed plasma concentration; C <sub>avg</sub>  = Average plasma concentration at steady-state;</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule" colspan="11" align="left" valign="top">T <sub>max</sub> = Time of occurrence of Cmax; t <sub>1/2 </sub>= Terminal elimination half-life. Regarding EM and PM <content styleCode="italics">[see Clincal Pharmacology, </content>
                                    <content styleCode="italics">Pharmacokinetics, Variability in Metabolism (12.3)].</content>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph ID="ID111">The mean oral bioavailability of darifenacin extended-release tablets in EMs at steady-state is estimated to be 15% and 19% for 7.5 mg and 15 mg tablets, respectively.</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Effect of Food</content>
                           </content>
                        </paragraph>
                        <paragraph>Following single dose administration of darifenacin extended-release tablets with food, the AUC of darifenacin was not affected, while the C <sub>max</sub> was increased by 22% and T <sub>max </sub>was shortened by 3.3 hours. There is no effect of food on multiple-dose pharmacokinetics from darifenacin extended-release tablets.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Distribution</content>
                        </paragraph>
                        <paragraph>Darifenacin is approximately 98 % bound to plasma proteins (primarily to alpha-1-acid-glycoprotein). The steady-state volume of distribution (Vss) is estimated to be 163 L.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Metabolism</content>
                        </paragraph>
                        <paragraph>Darifenacin is extensively metabolized by the liver following oral dosing.</paragraph>
                        <paragraph>Metabolism is mediated by cytochrome P450 enzymes CYP2D6 and CYP3A4. The three main metabolic routes are as follows:</paragraph>
                        <paragraph>(i)             monohydroxylation in the dihydrobenzofuran ring;</paragraph>
                        <paragraph>(ii)            dihydrobenzofuran ring opening;</paragraph>
                        <paragraph>(iii)           N-dealkylation of the pyrrolidine nitrogen.</paragraph>
                        <paragraph>The initial products of the hydroxylation and N-dealkylation pathways are the major circulating metabolites but they are unlikely to contribute significantly to the overall clinical effect of darifenacin.</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Variability in Metabolism</content>
                           </content>
                        </paragraph>
                        <paragraph>A subset of individuals (approximately 7% Caucasians and 2% African Americans) are poor metabolizers (PMs) of CYP2D6 metabolized drugs. Individuals with normal CYP2D6 activity are referred to as extensive metabolizers (EMs). The metabolism of darifenacin in PMs will be principally mediated via CYP3A4. The darifenacin ratios (PM versus EM) for C <sub>max</sub> and AUC following darifenacin 15 mg once daily at steady-state were 1.9 and 1.7, respectively.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Excretion</content>
                        </paragraph>
                        <paragraph>Following administration of an oral dose of <sup>14</sup>C-darifenacin solution to healthy volunteers, approximately 60% of the radioactivity was recovered in the urine and 40% in the feces. Only a small percentage of the excreted dose was unchanged darifenacin (3%). Estimated darifenacin clearance is 40 L/h for EMs and 32 L/h for PMs. The elimination half-life of darifenacin following chronic dosing is approximately 13 to 19 hours.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Drug-Drug Interactions</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">Effects of Other Drugs on Darifenacin</content>
                        </paragraph>
                        <paragraph>Darifenacin metabolism is primarily mediated by the cytochrome P450 enzymes CYP2D6 and CYP3A4. Therefore, inducers of CYP3A4 or inhibitors of either of these enzymes may alter darifenacin pharmacokinetics <content styleCode="italics">[see Drug Interactions ( <linkHtml href="#ID15">7</linkHtml>)] </content>.</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">CYP3A4 Inhibitors: </content>
                           </content>In a drug interaction study, when a 7.5 mg once daily dose of darifenacin was given to steady- state and co-administered with the potent CYP3A4 inhibitor ketoconazole 400 mg, mean darifenacin Cmax increased to 11.2 ng/mL for EMs (n = 10) and 55.4 ng/mL for one PM subject (n = 1). Mean AUC increased to 143 and 939 ng <content styleCode="bold">•</content>h/mL for EMs and for one PM subject, respectively. When a 15 mg daily dose of darifenacin was given with ketoconazole, mean darifenacin Cmax increased to 67.6 ng/mL and 58.9 ng/mL for EMs (n = 3) and one PM subject (n = 1), respectively. Mean AUC increased to 1,110 and 931 ng <content styleCode="bold">•</content>h/mL for EMs and for one PM subject, respectively <content styleCode="italics">[see Dosage and Administration (2) and Drug Interactions ( <linkHtml href="#ID54">7.1</linkHtml>)] </content>.</paragraph>
                        <paragraph>The mean C <sub>max</sub> and AUC of darifenacin following 30 mg once daily dosing at steady-state were 128% and 95% higher, respectively, in the presence of a moderate CYP3A4 inhibitor, erythromycin. Co-administration of fluconazole, a moderate CYP3A4 inhibitor and darifenacin 30 mg once daily at steady-state increased darifenacin C <sub>max</sub> and AUC by 88 % and 84 %, respectively <content styleCode="italics">[see Drug Interactions ( <linkHtml href="#ID54">7.1</linkHtml>)] </content>.</paragraph>
                        <paragraph>The mean C <sub>max</sub> and AUC of darifenacin following 30 mg once daily at steady-state were 42 % and 34 % higher, respectively, in the presence of cimetidine, a mixed CYP P450 enzyme inhibitor.</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">CYP2D6 Inhibitors: </content>
                           </content>Darifenacin exposure following 30 mg once daily at steady-state was 33 % higher in the presence of the potent CYP2D6 inhibitor paroxetine 20 mg <content styleCode="italics">[see Drug Interactions ( <linkHtml href="#ID55">7.2</linkHtml>)] </content>.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Effects of Darifenacin on Other Drugs</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">In Vitro Studies: </content>
                           </content>Based on <content styleCode="italics">in vitro </content>human microsomal studies, darifenacin extended-release tablets are not expected to inhibit CYP1A2 or CYP2C9 at clinically relevant concentrations.</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">In Vivo Studies: </content>
                           </content>The potential for clinical doses of darifenacin extended-release tablets to act as inhibitors of CYP2D6 or CYP3A4 substrates was investigated in specific drug interaction studies.</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">CYP2D6 Substrates: </content>
                           </content>The mean C <sub>max</sub> and AUC of imipramine, a CYP2D6 substrate, were increased by 57% and 70%, respectively, in the presence of steady-state darifenacin 30 mg once daily. The mean C <sub>max</sub> and AUC of desipramine, the active metabolite of imipramine, were increased by 260 % <content styleCode="italics">[see Drug Interactions ( <linkHtml href="#ID56">7.3</linkHtml>)] </content>.</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">CYP3A4 Substrates: </content>
                           </content>Darifenacin (30 mg daily) co-administered with a single oral dose of midazolam 7.5 mg resulted in a 17 % increase in midazolam exposure.</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Combination Oral Contraceptives: </content>
                           </content>Darifenacin (10 mg three times daily) had no effect on the pharmacokinetics of a combination oral contraceptive containing levonorgestrel (0.15 mg) and ethinyl estradiol (0.03 mg).</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Warfarin: </content>
                           </content>Darifenacin had no significant effect on prothrombin time when a single dose of warfarin 30 mg was co-administered with darifenacin (30 mg daily) at steady-state <content styleCode="italics">[see Drug Interactions ( <linkHtml href="#ID59">7.6</linkHtml>)] </content>.</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Digoxin: </content>
                           </content>Darifenacin (30 mg daily) co-administered with digoxin (0.25 mg) at steady-state resulted in a 16 % increase in digoxin exposure <content styleCode="italics">[see Drug Interactions ( <linkHtml href="#ID60">7.7</linkHtml>)] </content>.</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Pharmacokinetics in Special Populations</content>
                           </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Age: </content>
                           </content>A population pharmacokinetic analysis of patient data indicated a trend for clearance of darifenacin to decrease with age (6% per decade relative to a median age of 44). Following administration of darifenacin 15 mg once daily, darifenacin exposure at steady-state was approximately 12% to 19% higher in volunteers between 45 and 65 years of age compared to younger volunteers aged 18 to 44 years <content styleCode="italics">[</content>
                           <content styleCode="italics">see Use in Specific Populations ( <linkHtml href="#ID66">8.5</linkHtml>)]. </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Pediatric: </content>
                           </content>The pharmacokinetics of darifenacin extended-release tablets has not been studied in the pediatric population <content styleCode="italics">[see Use in Specific Populations ( <linkHtml href="#ID65">8.4</linkHtml>
                              <linkHtml href="#ID65">)</linkHtml>] </content>.</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Gender: </content>
                           </content>PK parameters were calculated for 22 male and 25 female healthy volunteers. Darifenacin Cmax and AUC at steady-state were approximately 57% to 79% and 61% to 73% higher in females than in males, respectively <content styleCode="italics">[see Use in Specific Populations ( <linkHtml href="#ID69">8.8</linkHtml>)] </content>.</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Renal Impairment: </content>
                           </content>A study of subjects with varying degrees of renal impairment (creatinine clearance between 10 and 136 mL/min) given darifenacin 15 mg once daily to steady-state demonstrated no clear relationship between renal function and darifenacin clearance <content styleCode="italics">[see Use in Specific Populations ( <linkHtml href="#ID68">8.7</linkHtml>)] </content>.</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Hepatic Impairment: </content>
                           </content>Darifenacin pharmacokinetics were investigated in subjects with mild (Child-Pugh A) or moderate (Child-Pugh B) impairment of hepatic function given darifenacin 15 mg once daily to steady-state. Mild hepatic impairment had no effect on the pharmacokinetics of darifenacin. However, protein binding of darifenacin was affected by moderate hepatic impairment. After adjusting for plasma protein binding, unbound darifenacin exposure was estimated to be 4.7-fold higher in subjects with moderate hepatic impairment than subjects with normal hepatic function. Subjects with severe hepatic impairment (Child-Pugh C) have not been studied <content styleCode="italics">[see Dosage and Administration (2), Warning and Precautions ( <linkHtml href="#ID50">5.5</linkHtml>) and Use in Specific Population ( <linkHtml href="#ID67">8.6</linkHtml>)] </content>.</paragraph>
                     </text>
                     <effectiveTime value="20250424"/>
                     <component>
                        <observationMedia ID="Le484c485-96dc-4963-b188-69c7edcad78a">
                           <text>Figure1</text>
                           <value mediaType="image/jpeg" xsi:type="ED">
                              <reference value="figure-1.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID20">
               <id root="b19d5618-737c-4740-9c4c-e98523af1be8"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY</title>
               <effectiveTime value="20250424"/>
               <component>
                  <section ID="ID74">
                     <id root="bbb6fe3b-b197-4c45-ba9d-405a77efc228"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
                     <text>
                        <paragraph ID="ID112">
                           <content styleCode="underline">
                              <content styleCode="italics">﻿Carcinogenesis</content>
                           </content>
                        </paragraph>
                        <paragraph>Carcinogenicity studies with darifenacin were conducted in mice and rats. No evidence of drug-related carcinogenicity was revealed in a 24-month study in mice at dietary doses up to 100 mg/kg/day or approximately 32 times the estimated free plasma AUC reached at the maximum recommended human dose (the AUC at the MRHD) of 15 mg and in a 24-month study in rats at doses up to 15 mg/kg/day or up to approximately 12 times the AUC at the MRHD in female rats and approximately eight times the AUC at the MRHD in male rats.</paragraph>
                        <paragraph>
                           <content styleCode="underline">
                              <content styleCode="italics">Mutagenesis</content>
                           </content>
                        </paragraph>
                        <paragraph>Darifenacin was not genotoxic in the bacterial mutation assay (Ames test), the Chinese hamster ovary assay, the human lymphocyte assay, or the <content styleCode="italics">in vivo </content>mouse bone marrow cytogenetics assay.</paragraph>
                        <paragraph>
                           <content styleCode="underline">
                              <content styleCode="italics">﻿Impairment of Fertility</content>
                           </content>
                        </paragraph>
                        <paragraph>There was no evidence for effects on fertility in male or female rats treated at oral doses associated with up to approximately 78 times (50 mg/kg/day) the AUC at the MRHD.</paragraph>
                     </text>
                     <effectiveTime value="20250424"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID21">
               <id root="e8d1fae2-fb96-44cd-af0c-c46e36ac1bfd"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>14 CLINICAL STUDIES</title>
               <text>
                  <paragraph ID="ID113">Darifenacin extended-release tablets were evaluated for the treatment of patients with overactive bladder with symptoms of urgency, urge urinary incontinence, and increased urinary frequency in three randomized, fixed-dose, placebo-controlled, multicenter, double-blind, 12-week studies (Studies 1, 2 and 3) and one randomized, double-blind, placebo-controlled, multicenter, dose-titration study (Study 4). For study eligibility in all four studies, patients with symptoms of overactive bladder for at least six months were required to demonstrate at least eight micturitions and at least one episode of urinary urgency per day, and at least five episodes of urge urinary incontinence per week. The majority of patients were white (94%) and female (84%), with a mean age of 58 years, range 19 to 93 years. Thirty-three percent of patients were greater than or equal to 65 years of age <content styleCode="italics">. </content>These characteristics were well balanced across treatment groups. The study population was inclusive of both naïve patients who had not received prior pharmacotherapy for overactive bladder (60%) and those who had (40%).</paragraph>
                  <paragraph>Table 4 shows the efficacy data collected from 7- or 14-day voiding diaries in the three fixed-dose placebo-controlled studies of 1,059 patients treated with placebo, 7.5 mg or 15 mg once daily darifenacin for 12 weeks. A significant decrease in the primary endpoint, change from baseline in average weekly urge urinary incontinence episodes was observed in all three studies. Data is also shown for two secondary endpoints, change from baseline in the average number of micturitions per day (urinary frequency) and change from baseline in the average volume voided per micturition.</paragraph>
                  <table ID="ID114" width="97%">
                     <caption> Table 4: Difference Between Darifenacin (7.5 mg, 15 mg) and Placebo for the Week 12 Change from Baseline (Studies 1, 2 and 3) </caption>
                     <colgroup>
                        <col width="17%"/>
                        <col width="11%"/>
                        <col width="11%"/>
                        <col width="7%"/>
                        <col width="11%"/>
                        <col width="11%"/>
                        <col width="7%"/>
                        <col width="11%"/>
                        <col width="9%"/>
                     </colgroup>
                     <tfoot>
                        <tr styleCode="First Last">
                           <td colspan="9" align="left">
                              <paragraph styleCode="First Footnote">*Indicates statistically significant difference versus placebo (p less than 0.05, Wilcoxon rank-sum test)</paragraph>
                           </td>
                        </tr>
                     </tfoot>
                     <tbody>
                        <tr>
                           <td styleCode="Toprule" align="left" valign="top"/>
                           <td styleCode="Rrule Toprule" colspan="3" align="center" valign="top">
                              <content styleCode="bold">
                                 <content styleCode="underline">Study 1</content>
                              </content>
                           </td>
                           <td styleCode="Rrule Toprule" colspan="3" align="center" valign="top">
                              <content styleCode="bold">
                                 <content styleCode="underline">Study 2</content>
                              </content>
                           </td>
                           <td styleCode="Toprule" colspan="2" align="center" valign="top">
                              <content styleCode="bold">
                                 <content styleCode="underline">Study 3</content>
                              </content>
                           </td>
                        </tr>
                        <tr>
                           <td align="left" valign="top"/>
                           <td align="left" valign="top"/>
                           <td align="center" valign="top"/>
                           <td styleCode="Rrule" align="left" valign="top"/>
                           <td align="left" valign="top"/>
                           <td align="left" valign="top"/>
                           <td styleCode="Rrule" align="left" valign="top"/>
                           <td align="left" valign="top"/>
                           <td align="left" valign="top"/>
                        </tr>
                        <tr>
                           <td styleCode="Botrule" align="left" valign="top"/>
                           <td styleCode="Botrule" align="left" valign="top">
                              <content styleCode="bold"> Darifenacin</content>
                              <br/>
                              <content styleCode="bold"> 7.5 mg</content>
                           </td>
                           <td styleCode="Botrule" align="left" valign="top">
                              <content styleCode="bold"> Darifenacin</content>
                              <br/>
                              <content styleCode="bold"> 15 mg</content>
                           </td>
                           <td styleCode="Botrule Rrule" align="left" valign="top">
                              <content styleCode="bold"> Placebo</content>
                           </td>
                           <td styleCode="Botrule" align="left" valign="top">
                              <content styleCode="bold"> Darifenacin</content>
                              <br/>
                              <content styleCode="bold"> 7.5 mg</content>
                           </td>
                           <td styleCode="Botrule" align="left" valign="top">
                              <content styleCode="bold"> Darifenacin</content>
                              <br/>
                              <content styleCode="bold"> 15 mg</content>
                           </td>
                           <td styleCode="Botrule Rrule" align="left" valign="top">
                              <content styleCode="bold"> Placebo</content>
                           </td>
                           <td styleCode="Botrule" align="left" valign="top">
                              <content styleCode="bold"> Darifenacin</content>
                              <br/>
                              <content styleCode="bold"> 15 mg</content>
                           </td>
                           <td styleCode="Botrule" align="left" valign="top">
                              <content styleCode="bold"> Placebo</content>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule" align="left" valign="top">
                              <content styleCode="bold"> No. of Patients </content>
                              <br/>
                              <content styleCode="bold"> Entered</content>
                           </td>
                           <td styleCode="Botrule" align="left" valign="top">229</td>
                           <td styleCode="Botrule" align="left" valign="top">115</td>
                           <td styleCode="Botrule Rrule" align="left" valign="top">164</td>
                           <td styleCode="Botrule" align="left" valign="top">108</td>
                           <td styleCode="Botrule" align="left" valign="top">107</td>
                           <td styleCode="Botrule Rrule" align="left" valign="top">109</td>
                           <td styleCode="Botrule" align="left" valign="top">112</td>
                           <td styleCode="Botrule" align="left" valign="top">115</td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule" colspan="9" align="left" valign="top">
                              <content styleCode="bold"> Urge Incontinence Episodes per Week</content>
                           </td>
                        </tr>
                        <tr>
                           <td align="left" valign="top">Median Baseline</td>
                           <td align="left" valign="top">16.3</td>
                           <td align="left" valign="top">17.0</td>
                           <td styleCode="Rrule" align="left" valign="top">16.6</td>
                           <td align="left" valign="top">14.0</td>
                           <td align="left" valign="top">17.3</td>
                           <td styleCode="Rrule" align="left" valign="top">16.1</td>
                           <td align="left" valign="top">16.2</td>
                           <td align="left" valign="top">15.5</td>
                        </tr>
                        <tr>
                           <td align="left" valign="top">Median Change <br/> from Baseline</td>
                           <td align="left" valign="top">-9.0</td>
                           <td align="left" valign="top">-10.4</td>
                           <td styleCode="Rrule" align="left" valign="top">-7.6</td>
                           <td align="left" valign="top">-8.1</td>
                           <td align="left" valign="top">-10.4</td>
                           <td styleCode="Rrule" align="left" valign="top">-5.9</td>
                           <td align="left" valign="top">-11.4</td>
                           <td align="left" valign="top">-9.0</td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule" align="left" valign="top">Median Difference to Placebo</td>
                           <td styleCode="Botrule" align="left" valign="top">-1.5*</td>
                           <td styleCode="Botrule" align="left" valign="top">
                              <br/> -2.1*</td>
                           <td styleCode="Botrule Rrule" align="left" valign="top">
                              <br/> -</td>
                           <td styleCode="Botrule" align="left" valign="top">
                              <br/> -2.8*</td>
                           <td styleCode="Botrule" align="left" valign="top">
                              <br/> -4.3*</td>
                           <td styleCode="Botrule Rrule" align="left" valign="top">
                              <br/> -</td>
                           <td styleCode="Botrule" align="left" valign="top">
                              <br/> -2.4*</td>
                           <td styleCode="Botrule" align="left" valign="top">
                              <br/> -</td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule" colspan="9" align="left" valign="top">
                              <content styleCode="bold"> Micturitions per Day</content>
                           </td>
                        </tr>
                        <tr>
                           <td align="left" valign="top">Median Baseline</td>
                           <td align="left" valign="top">10.1</td>
                           <td align="left" valign="top">10.1</td>
                           <td styleCode="Rrule" align="left" valign="top">10.1</td>
                           <td align="left" valign="top">10.3</td>
                           <td align="left" valign="top">11.0</td>
                           <td styleCode="Rrule" align="left" valign="top">10.1</td>
                           <td align="left" valign="top">10.5</td>
                           <td align="left" valign="top">10.4</td>
                        </tr>
                        <tr>
                           <td align="left" valign="top">Median Change <br/> from Baseline</td>
                           <td align="left" valign="top">-1.6</td>
                           <td align="left" valign="top">-1.7</td>
                           <td styleCode="Rrule" align="left" valign="top">-0.8</td>
                           <td align="left" valign="top">-1.7</td>
                           <td align="left" valign="top">-1.9</td>
                           <td styleCode="Rrule" align="left" valign="top">-1.1</td>
                           <td align="left" valign="top">-1.9</td>
                           <td align="left" valign="top">-1.2</td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule" align="left" valign="top">Median Difference to Placebo</td>
                           <td styleCode="Botrule" align="left" valign="top">-0.8*</td>
                           <td styleCode="Botrule" align="left" valign="top">-0.9*</td>
                           <td styleCode="Botrule Rrule" align="left" valign="top">-</td>
                           <td styleCode="Botrule" align="left" valign="top">-0.5</td>
                           <td styleCode="Botrule" align="left" valign="top">-0.7*</td>
                           <td styleCode="Botrule Rrule" align="left" valign="top">-</td>
                           <td styleCode="Botrule" align="left" valign="top">-0.5</td>
                           <td styleCode="Botrule" align="left" valign="top">-</td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule" colspan="9" align="left" valign="top">
                              <content styleCode="bold"> Volume of Urine Passed per Void (mL)</content>
                           </td>
                        </tr>
                        <tr>
                           <td align="left" valign="top">Median Baseline</td>
                           <td align="left" valign="top">160.2</td>
                           <td align="left" valign="top">151.8</td>
                           <td styleCode="Rrule" align="left" valign="top">162.4</td>
                           <td align="left" valign="top">161.7</td>
                           <td align="left" valign="top">157.3</td>
                           <td styleCode="Rrule" align="left" valign="top">162.2</td>
                           <td align="left" valign="top">155.0</td>
                           <td align="left" valign="top">147.1</td>
                        </tr>
                        <tr>
                           <td align="left" valign="top">Median Change <br/> from Baseline</td>
                           <td align="left" valign="top">14.9</td>
                           <td align="left" valign="top">30.9</td>
                           <td styleCode="Rrule" align="left" valign="top">7.6</td>
                           <td align="left" valign="top">16.8</td>
                           <td align="left" valign="top">23.6</td>
                           <td styleCode="Rrule" align="left" valign="top">7.1</td>
                           <td align="left" valign="top">26.7</td>
                           <td align="left" valign="top">4.6</td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule" align="left" valign="top">Median Difference to Placebo</td>
                           <td styleCode="Botrule" align="left" valign="top">9.1*</td>
                           <td styleCode="Botrule" align="left" valign="top">20.7*</td>
                           <td styleCode="Botrule Rrule" align="left" valign="top">-</td>
                           <td styleCode="Botrule" align="left" valign="top">9.2</td>
                           <td styleCode="Botrule" align="left" valign="top">16.6*</td>
                           <td styleCode="Botrule Rrule" align="left" valign="top">-</td>
                           <td styleCode="Botrule" align="left" valign="top">20.1*</td>
                           <td styleCode="Botrule" align="left" valign="top">-</td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph ID="ID115">Table 5 shows the efficacy data from the dose-titration study in 395 patients who initially received 7.5 mg darifenacin or placebo daily with the option to increase to 15 mg darifenacin or placebo daily after two weeks.</paragraph>
                  <table ID="ID116" width="678px">
                     <caption> Table 5: Difference between Darifenacin (7.5 mg/15 mg) and Placebo for the Week 12 Change from Baseline (Study 4) </caption>
                     <colgroup>
                        <col width="252"/>
                        <col width="228"/>
                        <col width="198"/>
                     </colgroup>
                     <tfoot>
                        <tr styleCode="First Last">
                           <td colspan="3" align="left">
                              <paragraph styleCode="First Footnote">*Indicates statistically significant difference versus placebo (p less than 0.05, Wilcoxon rank-sum test)</paragraph>
                           </td>
                        </tr>
                     </tfoot>
                     <tbody>
                        <tr>
                           <td styleCode="Botrule" valign="top"/>
                           <td styleCode="Botrule" align="left" valign="top">
                              <content styleCode="bold"> Darifenacin </content>
                              <br/>
                              <content styleCode="bold"> 7.5 mg /15 mg</content>
                           </td>
                           <td styleCode="Botrule" align="left" valign="top">
                              <content styleCode="bold"> Placebo</content>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule" align="left" valign="top">
                              <content styleCode="bold"> No. of Patients Treated</content>
                           </td>
                           <td styleCode="Botrule" align="left" valign="top">268</td>
                           <td styleCode="Botrule" align="left" valign="top">127</td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule" align="left" valign="top">
                              <content styleCode="bold"> Urge Incontinence Episodes per Week</content>
                           </td>
                           <td styleCode="Botrule" valign="top"/>
                           <td styleCode="Botrule" valign="top"/>
                        </tr>
                        <tr>
                           <td styleCode="Botrule" align="left" valign="top">Median Baseline <br/> Median Change from Baseline <br/> Median Difference to Placebo</td>
                           <td styleCode="Botrule" align="left" valign="top">16.0 <br/> -8.2 <br/> -1.4*</td>
                           <td styleCode="Botrule" align="left" valign="top">14.0 <br/> -6.0 <br/> -</td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule" align="left" valign="top">
                              <content styleCode="bold"> Micturitions per Day</content>
                           </td>
                           <td styleCode="Botrule" valign="top"/>
                           <td styleCode="Botrule" valign="top"/>
                        </tr>
                        <tr>
                           <td styleCode="Botrule" align="left" valign="top">Median Baseline <br/> Median Change from Baseline <br/> Median Difference to Placebo</td>
                           <td styleCode="Botrule" align="left" valign="top">9.9 <br/> -1.9 <br/> -0.8*</td>
                           <td styleCode="Botrule" align="left" valign="top">10.4 <br/> -1.0 <br/> -</td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule" align="left" valign="top">
                              <content styleCode="bold"> Volume of Urine Passed per Void (mL)</content>
                           </td>
                           <td styleCode="Botrule" valign="top"/>
                           <td styleCode="Botrule" valign="top"/>
                        </tr>
                        <tr>
                           <td align="left" valign="top">Median Baseline</td>
                           <td align="left" valign="top">173.7</td>
                           <td align="left" valign="top">177.2</td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule" align="left" valign="top">Median Change from Baseline <br/> Median Difference to Placebo</td>
                           <td styleCode="Botrule" align="left" valign="top">18.8 <br/> 13.3 *</td>
                           <td styleCode="Botrule" align="left" valign="top">6.6 <br/> -</td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph ID="ID117">As seen in Figures 2a, 2b and 2c, reductions in the number of urge incontinence episodes per week were observed within the first two weeks in patients treated with darifenacin 7.5 mg and 15 mg once daily compared to placebo. Further, these effects were sustained throughout the 12-week treatment period.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Figures 2a, 2b, 2c. Median Change from Baseline at Weeks 2, 6, 12 for Number of Urge Incontinence Episodes per Week (Studies 1, 2 and 3)</content>
                  </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="L58ab95c3-0f35-4155-8d87-a35b23be18db"/>
                  </paragraph>
                  <paragraph ID="ID143">
                     <content styleCode="bold">Figure 2a, Study 1</content>
                  </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="Lf0f315f9-44b2-4eb5-b938-323a44ad0073"/>
                  </paragraph>
                  <paragraph/>
                  <paragraph>
                     <content styleCode="bold">Figure 2b, Study 2</content>
                  </paragraph>
                  <paragraph/>
                  <paragraph>
                     <renderMultiMedia referencedObject="L1143cf7a-4ece-4ac5-96d0-d310cdd9ec4d"/>
                  </paragraph>
                  <paragraph/>
                  <paragraph>
                     <content styleCode="bold">Figure 2c, Study 3</content>
                  </paragraph>
               </text>
               <effectiveTime value="20250424"/>
               <component>
                  <observationMedia ID="L58ab95c3-0f35-4155-8d87-a35b23be18db">
                     <text>Figure 2a Study 1</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="figure2a-study1.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="Lf0f315f9-44b2-4eb5-b938-323a44ad0073">
                     <text>Figure 2b Study 2</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="figure2b-study2.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="L1143cf7a-4ece-4ac5-96d0-d310cdd9ec4d">
                     <text>Figure 2c Study 3</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="figure2c-study3.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID22">
               <id root="3524759d-8fa0-4f04-ab96-82deda9265e5"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING</title>
               <text>
                  <paragraph ID="ID121">Darifenacin extended-release tablets, 7.5 mg are white to off-white colored, round, biconvex, bevel edged, film coated tablets, debossed "202" on one side and plain on other side.</paragraph>
                  <paragraph>Bottle of 30.............................................................................................NDC 13668-202-30</paragraph>
                  <paragraph>Bottle of 90.............................................................................................NDC 13668-202-90</paragraph>
                  <paragraph>Bottle of 500..........................................................................................NDC 13668-202-05</paragraph>
                  <paragraph>Darifenacin extended-release tablets, 15 mg are light peach colored, round, biconvex, bevel edged, film coated tablets, debossed "203" on one side and plain on other side.</paragraph>
                  <paragraph>Bottle of 30........................................................................................... NDC 13668-203-30</paragraph>
                  <paragraph>Bottle of 90........................................................................................... NDC 13668-203-90</paragraph>
                  <paragraph>Bottle of 500..........................................................................................NDC 13668-203-05</paragraph>
                  <paragraph>
                     <content styleCode="bold">Storage</content>
                  </paragraph>
                  <paragraph>Store at 20° to 25°C (68° to 77°F); excursions permitted between 15°C and 30°C (59°F and 86°F) [see USP Controlled Room Temperature]. Protect from light.</paragraph>
                  <paragraph>Keep this and all drugs out of the reach of children.</paragraph>
               </text>
               <effectiveTime value="20250422"/>
            </section>
         </component>
         <component>
            <section ID="ID42">
               <id root="31e11523-c53c-4415-be2e-34cf7a520dc5"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17 PATIENT COUNSELING INFORMATION</title>
               <text>
                  <paragraph>8100851See FDA-approved patient labeling (Patient Information).</paragraph>
                  <paragraph>Patients should be informed that anticholinergic agents, such as darifenacin extended-release tablets, may produce clinically significant adverse effects related to anticholinergic pharmacological activity including constipation, urinary retention and blurred vision. Heat prostration (due to decreased sweating) can occur when anticholinergics such as darifenacin extended-release tablets are used in a hot environment. Because anticholinergics, such as darifenacin extended-release tablets, may produce dizziness or blurred vision, patients should be advised to exercise caution in decisions to engage in potentially dangerous activities until the drug's effects have been determined. Patients should read the patient information leaflet before starting therapy with darifenacin extended-release tablets.</paragraph>
                  <paragraph>Patients should be informed that darifenacin may produce clinically significant angioedema that may result in airway obstruction. Patients should be advised to promptly discontinue darifenacin therapy and seek immediate medical attention if they experience edema of the tongue or laryngopharynx, or difficulty breathing.</paragraph>
                  <paragraph>Darifenacin extended-release tablets should be taken once daily with water. They may be taken with or without food, and should be swallowed whole and not chewed, divided or crushed.</paragraph>
                  <paragraph/>
                  <paragraph>
                     <renderMultiMedia referencedObject="L811a401f-7515-466f-b38f-3e4d03b728b5"/>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Manufactured by:</content>
                  </paragraph>
                  <paragraph>TORRENT PHARMACEUTICALS LTD., INDIA.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Manufactured for:</content>
                  </paragraph>
                  <paragraph>TORRENT PHARMA INC., Basking Ridge, NJ 07920</paragraph>
                  <paragraph>8100851                                                 April 2025</paragraph>
               </text>
               <effectiveTime value="20250422"/>
               <component>
                  <observationMedia ID="L811a401f-7515-466f-b38f-3e4d03b728b5">
                     <text>logo1</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="06torrentlogo1.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="L53d2babb-28b4-48b9-a892-b8cc2a11e645">
               <id root="ec5b0953-8086-4739-a00d-09d0f61f36d6"/>
               <code code="42230-3" codeSystem="2.16.840.1.113883.6.1" displayName="SPL PATIENT PACKAGE INSERT SECTION"/>
               <text>
                  <paragraph>
                     <content styleCode="bold">FDA-Approved Patient Labeling</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Darifenacin (DAR-i-FEN-a-sin)Extended-Release Tablets</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Read this Patient Information leaflet about darifenacin extended-release tablets before you start taking it and each time you get a refill. There may be new information. This leaflet does not take the place of talking to your doctor about your medical condition or your treatment.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">What is darifenacin extended-release tablets?</content>
                  </paragraph>
                  <paragraph>Darifenacin extended-release tablets is a prescription medicine for adults used to treat the following symptoms due to a condition called overactive bladder:</paragraph>
                  <list listType="unordered">
                     <item>  Urge urinary incontinence: a strong need to urinate with leaking or wetting accidents</item>
                     <item>  Urgency: a strong need to urinate right away</item>
                     <item>  Frequency: urinating often</item>
                  </list>
                  <paragraph>It is unknown if darifenacin extended-release tablets is safe and effective in children.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Who should not take darifenacin extended-release tablets?</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Do not take darifenacin extended-release tablets if you:</content>
                  </paragraph>
                  <list listType="unordered">
                     <item>  are not able to empty your bladder ("urinary retention")</item>
                     <item>  have delayed or slow emptying of your stomach ("gastric retention")</item>
                     <item>  have an eye problem called "uncontrolled narrow-angle glaucoma"</item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">What should I tell my healthcare provider before starting darifenacin extended-release tablets?</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Before starting darifenacin extended-release tablets, tell your doctor if you:</content>
                  </paragraph>
                  <list listType="unordered">
                     <item>  have trouble emptying your bladder or if you have a weak urine stream</item>
                     <item>  have any stomach or intestinal problems, or problems with constipation</item>
                     <item>  have liver problems</item>
                     <item>  have any other medical conditions</item>
                     <item>  are pregnant or are planning to become pregnant. It is not known if darifenacin extended-release tablets can harm your unborn baby.</item>
                     <item>  are breastfeeding or plan to breastfeed. It is not known if darifenacin passes into breast milk and if it can harm your baby. Talk to your doctor about the best way to feed your baby if you take darifenacin extended-release tablets.</item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">Tell your healthcare provider about all the medicines you take, </content>including prescription and non-prescription medicines, vitamins, and herbal supplements. Darifenacin extended-release tablets and certain other medicines may affect each other, causing side effects.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Especially tell your healthcare provider if you take a:</content>
                  </paragraph>
                  <list listType="unordered">
                     <item>antifungal medicine ketoconazole (Nizoral®) or itraconazole (Sporanox®)</item>
                     <item>antibiotic medicine clarithromycin (Biaxin®)</item>
                     <item>anti-HIV medicine ritonavir (Norvir®) or nelfinavir (Viracept®)</item>
                     <item>medicine to treat depression nefazadone (Serzone®)</item>
                     <item>medicine to treat an abnormal heartbeat flecainide (Tambocor<sup>TM</sup>)</item>
                     <item>antipsychotic medicine thioridazine (Mellaril®)</item>
                     <item>medicine to treat depression called a tricyclic antidepressant</item>
                  </list>
                  <paragraph>Know all the medicines you take. Keep a list of them with you to show your doctor and pharmacist each time you get a new medicine.</paragraph>
                  <paragraph>
                     <content styleCode="bold">How should I take darifenacin extended-release tablets?</content>
                  </paragraph>
                  <list listType="unordered">
                     <item>  Take darifenacin extended-release tablets exactly as prescribed. Your doctor will prescribe the dose that is right for you. Take darifenacin extended-release tablets 1 time daily with water.</item>
                     <item>  Darifenacin extended-release tablets should be swallowed whole. Do not chew, cut or crush darifenacin extended-release tablets.</item>
                     <item>  Darifenacin extended-release tablets may be taken with or without food.</item>
                     <item>  If you take too much darifenacin extended-release tablets call your doctor or go to the nearest hospital emergency room right away.</item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">What should I avoid while taking darifenacin extended-release tablets?</content>
                  </paragraph>
                  <paragraph>Darifenacin extended-release tablets can cause blurred vision or dizziness. Do not drive or operate heavy machinery until you know how darifenacin extended-release tablets affects you.</paragraph>
                  <paragraph>
                     <content styleCode="bold">What are the possible side effects of darifenacin extended-release tablets?</content>
                  </paragraph>
                  <paragraph>Darifenacin extended-release tablets may cause serious side effects including:</paragraph>
                  <list listType="unordered">
                     <item>
                        <content styleCode="bold">Serious allergic reaction. </content>Stop taking darifenacin extended-release tablets and get medical help right away if you have:</item>
                     <item>  hives, skin rash or swelling</item>
                     <item>  severe itching</item>
                     <item>  swelling of your face, mouth or tongue</item>
                     <item>  trouble breathing</item>
                  </list>
                  <paragraph>The most common side effects with darifenacin extended-release tablets are:</paragraph>
                  <list listType="unordered">
                     <item>constipation</item>
                     <item>dry mouth</item>
                     <item>headache</item>
                     <item>heartburn</item>
                     <item>nausea</item>
                     <item>urinary tract infection</item>
                     <item>blurred vision</item>
                     <item>heat exhaustion or heat-stroke. This can happen when darifenacin extended-release tablets are used in hot environments. Symptoms of heat exhaustion may include:</item>
                     <item>decreased sweating</item>
                     <item>dizziness</item>
                     <item>tiredness</item>
                     <item>nausea</item>
                     <item>increase body temperature</item>
                  </list>
                  <paragraph>Tell your doctor if you have any side effect that bothers you or that does not go away.</paragraph>
                  <paragraph>These are not all the possible side effects of darifenacin extended-release tablets. For more information, ask your doctor or pharmacist.</paragraph>
                  <paragraph>Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</paragraph>
                  <paragraph>
                     <content styleCode="bold">How do I store darifenacin extended-release tablets?</content>
                  </paragraph>
                  <paragraph>Store darifenacin extended-release tablets at 20° to 25°C (68° to 77°F); excursions permitted between 15°C and 30°C (59°F and 86°F) [see USP Controlled Room Temperature]. Protect from light.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Keep darifenacin extended-release tablets and all medicines out of the reach of children.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">General information about darifenacin extended-release tablets.</content>
                  </paragraph>
                  <paragraph>Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use darifenacin extended-release tablets for a condition for which it was not prescribed. Do not give darifenacin extended-release tablets to other people, even if they have the same symptoms you have. It may harm them.</paragraph>
                  <paragraph>This Patient Information leaflet summarizes the most important information about darifenacin extended-release tablets. If you would like more information, talk with your doctor. You can ask your pharmacist or doctor for information about darifenacin extended-release tablets that is written for health professionals.</paragraph>
                  <paragraph>
                     <content styleCode="bold">What are the ingredients in darifenacin extended-release tablets?</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Active ingredient: </content>darifenacin</paragraph>
                  <paragraph>
                     <content styleCode="bold">Inactive ingredients: </content>colloidal silicon dioxide, hypromellose (E15 LV), hypromellose (methocel K4M CR), magnesium stearate, microcrystalline cellulose, polyethylene glycol 400, talc and titanium dioxide.</paragraph>
                  <paragraph>The 15 mg tablet also contains ferric oxide red and ferric oxide yellow.</paragraph>
                  <paragraph>The brands listed are the trademarks of their respective owners.</paragraph>
                  <paragraph>This Patient Information has been approved by the U.S. Food and Drug Administration.</paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="L191452ab-95b7-4880-8b99-1efd4cd483c0"/>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Manufactured by:</content>
                  </paragraph>
                  <paragraph>TORRENT PHARMACEUTICALS LTD., INDIA.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Manufactured for:</content>
                  </paragraph>
                  <paragraph>TORRENT PHARMA INC., Basking Ridge, NJ 07920</paragraph>
                  <paragraph>8100850                                                   April 2025</paragraph>
               </text>
               <effectiveTime value="20250424"/>
               <component>
                  <observationMedia ID="L191452ab-95b7-4880-8b99-1efd4cd483c0">
                     <text>logo2</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="07torrentlogo2.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID145">
               <id root="be3aa911-d1e8-4eea-8342-ea874ffe8b06"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PACKAGE LABEL.PRINCIPAL DISPLAY PANEL</title>
               <text>
                  <paragraph>
                     <content styleCode="bold">Darifenacin Extended-Release Tablets 7.5 mg: Bottle of 30 Tablets</content>
                  </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="L979d9040-980b-44d8-ab4a-81addc876c62"/>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Darifenacin Extended-Release Tablets 15 mg: Bottle of 30 Tablets</content>
                  </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="L85a54e4a-37f9-4934-b9fd-62de51a41397"/>
                  </paragraph>
               </text>
               <effectiveTime value="20250424"/>
               <component>
                  <observationMedia ID="L979d9040-980b-44d8-ab4a-81addc876c62">
                     <text>75mg30counts</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="75mg-30s.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="L85a54e4a-37f9-4934-b9fd-62de51a41397">
                     <text>15mg100carton</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="15mg-30s.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>